AtriCure (NASDAQ:ATRC) Rating Increased to B at TheStreet

AtriCure (NASDAQ:ATRC) was upgraded by research analysts at TheStreet from a “c+” rating to a “b” rating in a note issued to investors on Tuesday, TheStreetRatingsTable reports.

Other analysts have also issued research reports about the stock. Needham & Company LLC lifted their price objective on shares of AtriCure from $90.00 to $92.00 and gave the company a “buy” rating in a research note on Thursday, November 4th. Zacks Investment Research lowered shares of AtriCure from a “buy” rating to a “hold” rating in a research note on Friday, November 19th. SVB Leerink lifted their price objective on shares of AtriCure from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Thursday, November 4th. Canaccord Genuity lifted their price objective on shares of AtriCure from $102.00 to $120.00 and gave the company a “buy” rating in a research note on Thursday, August 5th. Finally, Oppenheimer lowered shares of AtriCure from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 5th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, AtriCure presently has a consensus rating of “Buy” and a consensus target price of $91.11.

NASDAQ:ATRC opened at $76.72 on Tuesday. The firm’s 50 day simple moving average is $74.61 and its 200 day simple moving average is $75.89. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.63 and a quick ratio of 2.91. AtriCure has a one year low of $42.26 and a one year high of $89.18. The company has a market cap of $3.52 billion, a PE ratio of 80.76 and a beta of 1.10.

AtriCure (NASDAQ:ATRC) last posted its earnings results on Wednesday, November 3rd. The medical device company reported $2.11 EPS for the quarter, topping the consensus estimate of ($0.28) by $2.39. AtriCure had a net margin of 17.53% and a negative return on equity of 11.12%. The business had revenue of $70.46 million for the quarter, compared to the consensus estimate of $68.95 million. During the same period last year, the company earned ($0.11) EPS. Equities research analysts expect that AtriCure will post -1.21 EPS for the current year.

In other AtriCure news, Director Mark A. Collar sold 4,000 shares of AtriCure stock in a transaction on Thursday, November 4th. The shares were sold at an average price of $80.91, for a total transaction of $323,640.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Angela L. Wirick sold 2,604 shares of the business’s stock in a transaction dated Thursday, November 4th. The stock was sold at an average price of $85.00, for a total transaction of $221,340.00. The disclosure for this sale can be found here. Insiders have sold a total of 32,672 shares of company stock valued at $2,521,905 in the last 90 days. 3.60% of the stock is currently owned by company insiders.

Several large investors have recently modified their holdings of the stock. Captrust Financial Advisors boosted its holdings in shares of AtriCure by 5.6% in the 3rd quarter. Captrust Financial Advisors now owns 2,544 shares of the medical device company’s stock worth $177,000 after buying an additional 135 shares during the last quarter. BNP Paribas Arbitrage SA boosted its holdings in shares of AtriCure by 387.0% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 8,050 shares of the medical device company’s stock worth $560,000 after buying an additional 6,397 shares during the last quarter. Janus Henderson Group PLC purchased a new position in shares of AtriCure in the 3rd quarter worth about $301,000. Brookfield Asset Management Inc. bought a new stake in AtriCure in the 3rd quarter valued at about $1,391,000. Finally, Squarepoint Ops LLC raised its stake in AtriCure by 457.1% in the 3rd quarter. Squarepoint Ops LLC now owns 19,977 shares of the medical device company’s stock valued at $1,389,000 after acquiring an additional 16,391 shares during the period. 96.26% of the stock is currently owned by institutional investors.

About AtriCure

AtriCure, Inc engages in the development, manufacture, and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration.

Read More: What is the S&P 500 Index?

Analyst Recommendations for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.